Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FTO | Q9C0B1 | 10/20 | 0.70 |
| ▸ | MAPT | P10636 | 4/20 | 0.70 |
| ▸ | MEN1 | O00255 | 3/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.70 |
| ▸ | HTT | P42858 | 2/20 | 0.70 |
| ▸ | HPGD | P15428 | 2/20 | 0.70 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.70 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.70 |
| ▸ | RECQL | P46063 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.70 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.70 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.54 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.54 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fluorescein SCHEMBL19128333 | 0.99 | FTO (0.69) | FTOMAPTMEN1KMT2AHTT | |
| Fluorescein SCHEMBL20764877 | 0.99 | FTO (0.69) | FTOMAPTMEN1KMT2AHTT | |
| Fluorescein SCHEMBL5886626 | 0.99 | FTO (0.69) | FTOMAPTMEN1KMT2AHTT | |
| Fluorescein SCHEMBL14776969 | 0.99 | FTO (0.69) | FTOMAPTMEN1KMT2AHTT | |
| Fluorescein SCHEMBL27939701 | 0.99 | FTO (0.69) | FTOMAPTMEN1KMT2AHTT | |
| Fluorescein SCHEMBL1899996 | 0.97 | FTO (0.72) | FTOMAPTMEN1KMT2AHTT | |
| Fluorescein SCHEMBL28455275 | 0.93 | FTO (0.61) | FTOMAPTMEN1KMT2AHTT | |
| Fluorescein SCHEMBL27157745 | 0.92 | FTO (0.75) | FTOMAPTMEN1KMT2AHTT | |
| Fluorescein SCHEMBL10388070 | 0.92 | FTO (0.75) | FTOMAPTMEN1KMT2AHTT | |
| Fluorescein SCHEMBL27157742 | 0.91 | FTO (0.77) | FTOMAPTMEN1KMT2AHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023223039-A1 | IMPROVED POLYMER DEGRADING ENZYMES | CAMBRIDGE ENTERPRISE LIMITED (GB) | 2023-11-23 | — | — | WO | disclosed |
| EP-3491143-A1 | SPECIFIC SUBSTRATE OF AN ALDH ISOENZYME | Advanced Biodesign (FR) | 2019-06-05 | — | — | EP | disclosed |
| EP-2126122-A1 | METHOD AND TEST KIT FOR DETERMINING THE AMOUNTS OF TARGET SEQUENCES AND NUCLEOTIDE VARIATIONS THEREIN | Valtion Teknillinen Tutkimuskeskus (FI) | 2009-12-02 | — | — | EP | disclosed |
| US-20090011944-A1 | METHOD AND TEST KIT FOR DETECTING NUCLEOTIDE VARIATIONS | VALTION TEKNILLINEN TUTKIMUSKEKUS (FI) | 2009-01-08 | — | — | US | disclosed |
| WO-2008102057-A9 | METHOD AND TEST KIT FOR DETERMINING THE AMOUNTS OF TARGET SEQUENCES AND NUCLEOTIDE VARIATIONS THEREIN | VALTION TEKNILLINEN (FI) | 2008-10-09 | — | — | WO | disclosed |
| WO-2008102057-A1 | METHOD AND TEST KIT FOR DETERMINING THE AMOUNTS OF TARGET SEQUENCES AND NUCLEOTIDE VARIATIONS THEREIN | VALTION TEKNILLINEN TUTKIMUSKESKUS (FI) | 2008-08-28 | — | — | WO | disclosed |
| EP-1287012-B1 | NUCLEOTIDE ANALOGUES COMPRISING A REPORTER MOIETY AND A POLYMERASE ENZYME BLOCKING MOIETY | GE HEALTHCARE UK LTD (GB) | 2007-07-25 | — | — | EP | disclosed |
| US-7078499-B2 | Nucleotide analogues comprising a reporter moiety and a polymerase enzyme blocking moiety | GE HEALTHCARE UK LIMITED (GB) | 2006-07-18 | — | — | US | disclosed |
| US-20030194722-A1 | Nucleotide analogues comprising a reporter moiety and a polymerase enzyme blocking moiety | GE HEALTHCARE UK LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030194722-A1 | Nucleotide analogues comprising a reporter moiety and a polymerase enzyme blocking moiety | POLB, POLA1, XRN2 | FTO 2233/4885MAPT 3830/4885MEN1 2733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.